Description
OVERVIEWProduct overview
IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1 carrying an arginine substitution at position 3 and a 13-residue N-terminal extension.
Those modifications substantially reduce binding to IGF binding proteins, which is why the analogue is widely used as a supplement to serum-free cell culture media.
It is a research reagent. It is not a medicine and is not for human or veterinary use.
SUPPLY IN IRELANDIGF-1 LR3 Ireland — supplied to research laboratories
Research groups across Ireland buy IGF-1 LR3 from Kensington Laboratories as a lyophilised IGF-1 LR3 peptide, released only against a batch-matched certificate of analysis. Every vial of high purity IGF-1 LR3 is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering IGF-1 LR3 in Ireland receive material with documented purity and identity.
Laboratory IGF-1 LR3 is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning IGF1LR3 research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for IGF-1 LR3 peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
IGF-1 LR3 is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 1 mg per vial
- Peptide class: 83-amino-acid analogue of human IGF-1
- Also known as: Long R3 insulin-like growth factor 1
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1 carrying an arginine substitution at position 3 and a 13-residue N-terminal extension.
Those modifications substantially reduce binding to IGF binding proteins, which is why the analogue is widely used as a supplement to serum-free cell culture media.
It is a research reagent. It is not a medicine and is not for human or veterinary use.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Serum-free cell culture supplementation
- Cell proliferation and survival assays
- Myogenesis and satellite cell models
- IGF-1 receptor and Akt pathway signalling
Scientific context and proposed mechanisms
The analogue signals through the IGF-1 receptor and the downstream PI3K–Akt and MAPK pathways associated with proliferation and protein synthesis.
Reduced binding protein affinity increases the fraction available to the receptor in culture, which is the practical reason for its use as a media supplement.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-IGF1LR3-2405A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 14 May 2026
- Reported purity
- 99.17%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
